Serplulimab (Not yet branded)
Immunotherapy
Description
Serplulimab is a monoclonal antibody immunotherapy agent that targets the PD-1 (programmed death-1) receptor on T cells. In colorectal cancer treatment, it is used in combination regimens with chemotherapy, targeted therapies, and radiation therapy for both locally advanced and metastatic disease. The drug shows particular application in microsatellite stable (MSS) colorectal cancers, which typically respond poorly to single-agent immunotherapy. Clinical trials have evaluated serplulimab in neoadjuvant settings for locally advanced colon cancer and in multimodal treatment approaches for rectal cancer with oligometastases.
Mechanism of Action
Serplulimab binds to the PD-1 receptor on activated T lymphocytes, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signals that normally suppress T cell activation, thereby enhancing the immune system's ability to recognize and attack cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 18 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.